Carma Fund

Carma Fund is an early-stage venture capital firm dedicated to advancing life sciences and healthcare technologies. Established in June 2022, the fund has approximately €50 million under management and is based in Munich and Frankfurt am Main, Germany. It focuses on high-potential, early-stage life-science start-ups and projects, sourcing opportunities from partner institutions and other European academic organizations. The fund's investment areas include Med-Tech, Health-Tech, and Bio-Tech, with typical investments ranging from €100,000 to €1.5 million. Carma Fund is uniquely suited for young European companies and projects in the life science and medical space due to its extended investment horizon, flexible investment modes, and close relationships with leading technology transfer offices and industry partners. The fund's first closing was in June 2022, with a target size of €60 million. Its portfolio includes companies like Symphera, a Munich-based startup revolutionizing laparoscopic surgery with an innovative system designed to eliminate the need for manual instrument changes. Symphera secured €2.4 million in seed financing in September 2024, with Carma Fund participating alongside other investors. This investment aligns with Carma Fund's mission to support innovative solutions that improve patient outcomes and advance medical technologies. The fund's strategic approach and commitment to fostering early-stage developments in the life sciences and healthcare sectors position it as a significant player in the European venture capital landscape. Carma Fund's collaborative efforts with academic institutions and industry leaders underscore its dedication to translating scientific research into practical applications that benefit society. Through its investments, Carma Fund aims to drive innovation and contribute to the advancement of healthcare solutions across Europe.